Bucyrus (BUCY) Reports Strong Q3 Results
More News related to BUCY
- Bucyrus to Present at Robert W. Baird & Co. Conference
- Bucyrus to Present at Goldman Sachs Industrials Conference
- Bucyrus International Up After BUYINS.NET Report Predicted Strength After Earnings
- Morning Movers 10/23: AMZN, CPWR, EPAY, ALGN, HWAY, SCSS, ACO Higher; ELN, SNV, CBRX, RMTR, STSA, DVAX Lower
- Bucyrus (BUCY) Reports Strong Q3 Results
More News related to Earnings
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
Bucyrus International Inc. (NASDAQ: BUCY) reports Q3 EPS of $1.21, versus the analyst estimate of $0.86. Revenue for the quarter was $675.8 million, which compares to the estimate of $623.38 million.
Related Categories
EarningsStocks Mentioned
+2.31Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
